FDR1

51.8

-1.71%↓

HR

17.41

-2.14%↓

WDP

22.38

-0.09%↓

SLG

38.67

-2.5%↓

COVH.FR

22.3

+0.9%↑

FDR1

51.8

-1.71%↓

HR

17.41

-2.14%↓

WDP

22.38

-0.09%↓

SLG

38.67

-2.5%↓

COVH.FR

22.3

+0.9%↑

FDR1

51.8

-1.71%↓

HR

17.41

-2.14%↓

WDP

22.38

-0.09%↓

SLG

38.67

-2.5%↓

COVH.FR

22.3

+0.9%↑

FDR1

51.8

-1.71%↓

HR

17.41

-2.14%↓

WDP

22.38

-0.09%↓

SLG

38.67

-2.5%↓

COVH.FR

22.3

+0.9%↑

FDR1

51.8

-1.71%↓

HR

17.41

-2.14%↓

WDP

22.38

-0.09%↓

SLG

38.67

-2.5%↓

COVH.FR

22.3

+0.9%↑

Search

Gecina SA.

Fechado

SetorImobiliário

66.1 -0.53

Visão Geral

Variação de preço das ações

24h

Atual

Mín

65.95

Máximo

67.2

Indicadores-chave

By Trading Economics

Rendimento

-129M

160M

Vendas

-228M

243M

P/E

Médio do Setor

11.642

67.236

Rendimento de Dividendos

7.9

Margem de lucro

65.974

Funcionários

442

EBITDA

-120M

163M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+47.44% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

7.90%

6.64%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-367M

5.2B

Abertura anterior

66.63

Fecho anterior

66.1

Sentimento de Notícias

By Acuity

40%

60%

50 / 167 Ranking em Real estate

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Gecina SA. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de mar. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 de mar. de 2026, 22:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 de mar. de 2026, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

23 de mar. de 2026, 23:59 UTC

Conversa de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 de mar. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 de mar. de 2026, 23:37 UTC

Conversa de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Global Equities Roundup: Market Talk

23 de mar. de 2026, 22:42 UTC

Conversa de Mercado
Notícias Principais

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 de mar. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 de mar. de 2026, 22:23 UTC

Conversa de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 de mar. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 de mar. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 de mar. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 de mar. de 2026, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 de mar. de 2026, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 de mar. de 2026, 22:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 de mar. de 2026, 22:08 UTC

Conversa de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de mar. de 2026, 21:42 UTC

Conversa de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 de mar. de 2026, 21:32 UTC

Ganhos

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 de mar. de 2026, 21:10 UTC

Notícias Principais

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

23 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos
Notícias Principais

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Gecina SA. Previsão

Preço-alvo

By TipRanks

47.44% parte superior

Previsão para 12 meses

Média 97.75 EUR  47.44%

Máximo 118 EUR

Mínimo 80 EUR

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Gecina SA. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

2

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

90.45 / 92.5Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

50 / 167 Ranking em Imobiliário

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Gecina SA.

As a specialist for centrality and uses, Gecina operates innovative and sustainable living spaces. A real estate investment company, Gecina owns, manages and develops a unique portfolio at the heart of the Paris Region's central areas, with more than 1.2 million sq.m of offices and more than 9,000 housing units, almost three-quarters of which are located in Paris City or Neuilly-sur-Seine. These portfolios are valued at 17.1 billion euros at end-June 2024. Gecina has firmly established its focus on innovation and its human approach at the heart of its strategy to create value and deliver on its purpose: "Empowering shared human experiences at the heart of our sustainable spaces". For our 100,000 clients, this ambition is supported by our client-centric brand YouFirst. It is also positioned at the heart of UtilesEnsemble, our program setting out our solidarity-based commitments to the environment, to people and to the quality of life in cities. Gecina is a French real estate investment trust (SIIC) listed on Euronext Paris, and is part of the SBF 120, CAC Next 20, CAC Large 60 and CAC 40 ESG indices. Gecina is also recognized as one of the top-performing companies in its industry by leading sustainability benchmarks and rankings (GRESB, Sustainalytics, MSCI, ISS-ESG and CDP).
help-icon Live chat